O'Gorman C - Search Results

1

Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications.

Bowden CL, Karayal ON, Schwartz JH, Gundapaneni BK, O'Gorman C. Bowden CL, et al. J Affect Disord. 2013 Jan 10;144(1-2):171-5. doi: 10.1016/j.jad.2012.04.024. Epub 2012 Sep 21. J Affect Disord. 2013. PMID: 22999893 Clinical Trial.

2

Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.

Camm AJ, Karayal ON, Meltzer H, Kolluri S, O'Gorman C, Miceli J, Tensfeldt T, Kane JM. Camm AJ, et al. CNS Drugs. 2012 Apr 1;26(4):351-65. doi: 10.2165/11599010-000000000-00000. CNS Drugs. 2012. PMID: 22452529

3

Achieving and sustaining remission in bipolar I disorder with ziprasidone : a post hoc analysis of a 24-week, double-blind, placebo-controlled study.

Pae CU, Masand PS, Mandel FS, O'Gorman C. Pae CU, et al. Clin Drug Investig. 2012 Nov;32(11):747-54. doi: 10.1007/s40261-012-0009-1. Clin Drug Investig. 2012. PMID: 23026845 Clinical Trial.

4

Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.

Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano R, O'Gorman C, Harrigan RH. Miceli JJ, et al. Pharmacotherapy. 2010 Feb;30(2):127-35. doi: 10.1592/phco.30.2.127. Pharmacotherapy. 2010. PMID: 20099987 Clinical Trial.

5

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.

Correll CU, Davis RE, Weingart M, Saillard J, O'Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S, Vanover KE. Correll CU, et al. JAMA Psychiatry. 2020 Apr 1;77(4):349-358. doi: 10.1001/jamapsychiatry.2019.4379. JAMA Psychiatry. 2020. PMID: 31913424 Free PMC article. Clinical Trial.

6

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.

Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano RJ, O'Gorman C, Harrigan RH. Miceli JJ, et al. Clin Ther. 2010 Mar;32(3):472-91. doi: 10.1016/j.clinthera.2010.03.003. Clin Ther. 2010. PMID: 20399985 Clinical Trial.

7

Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.

O'Gorman C, Kapur S, Kolluri S, Kane J. O'Gorman C, et al. Hum Psychopharmacol. 2011 Jun-Jul;26(4-5):282-90. doi: 10.1002/hup.1200. Epub 2011 Jun 2. Hum Psychopharmacol. 2011. PMID: 21638329 Clinical Trial.

8

Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.

Simpson GM, O'Gorman CJ, Loebel A, Yang R. Simpson GM, et al. CNS Spectr. 2008 Oct;13(10):898-905. doi: 10.1017/s1092852900017004. CNS Spectr. 2008. PMID: 18955945 Clinical Trial.

9

Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.

Masand P, O'Gorman C, Mandel FS. Masand P, et al. Schizophr Res. 2011 Mar;126(1-3):174-83. doi: 10.1016/j.schres.2010.10.024. Epub 2010 Dec 24. Schizophr Res. 2011. PMID: 21185155

10

The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: a focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization.

Nasrallah HA, Harvey PD, Casey D, Csoboth CT, Hudson JI, Julian L, Lentz E, Nuechterlein KH, Perkins DO, Kotowsky N, Skale TG, Snowden LR, Tandon R, Tek C, Velligan D, Vinogradov S, O'Gorman C. Nasrallah HA, et al. Schizophr Res. 2015 Aug;166(1-3):69-79. doi: 10.1016/j.schres.2015.04.031. Epub 2015 May 28. Schizophr Res. 2015. PMID: 26027848

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

227 results

Search Page